Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

Number of Participants who Received a Dose of Protein C in Retrospective Study

Number of participants who received a dose of Protein C in retrospective study will be reported.

Time frame: Throughout the study period (up to 6 months)

Number of Participants with Prophylactic Treatment Outcome

Participants experience any episodes of purpura fulminans (PF), coumarin induced skin necrosis (CISN), or thromboembolic event during prophylactic treatment will be assessed.

Time frame: Throughout the study period (up to 6 months)

Number of Participants with Acute Episode Treatment Outcome

Acute episode treatment outcome includes type of episode (PF, CISN, Thromboembolic); Was treatment effective or not effective; Was patient successfully transitioned to anticoagulation following the resolution of the episode will be assessed.

Time frame: Throughout the study period (up to 6 months)

Number of Participants with Adverse Experiences (AEs) Related to Protein C Concentrate Treatment

An AE is defined as any untoward medical occurrence in a participant administered study product that does not necessarily have a casual relationship with the treatment. AEs considered possibly or probably related to Protein C Concentrate treatment will be recorded on case report forms (CRFs).

Time frame: Throughout the study period (up to 6 months)